Overview
Rejuvenate Biomed is a science-based healthy aging company dedicated to the discovery and development of therapeutics to impact the onset of multiple age-related diseases. The company is conducting a Phase 2 clinical trial of its lead asset RJx-01, a first-in-class multi-pathway therapeutic targeting COPD-induced sarcopenia and muscle weakness, with topline data expected by year-end 2026.
Key people
In the news
- July 4th is World Sarcopenia Day Sarcopenia, the progressive loss of muscle strength and function, is no longer just a consequence of ageing. It is a serious, underdiagnosed condition that drives frailty, disability, and loss of independence, with major implications for patients and healthcare systems worldwide. On #WorldSarcopeniaDay, it is important to recognize that addressing sarcopenia requires more than awareness, it requires action. While developing effective treatments for patients with established sarcopenia is
- BIO2026: a week full of inspiration, insights, and meaningful connections The BIO International Convention once again proved to be the world’s leading gathering for biotech, pharma, and investors, and we were proud to be part of it. At Rejuvenate Biomed, we came back energized by: 🔹 Inspiring panel discussions and expert presentations 🔹 New insights and valuable learnings 🔹 Engaging and productive meetings with current and new stakeholders We were particularly encouraged by the strong interest in both: ✅ RJx-01, in clinical
- Team spirit in action 💪✨ At Rejuvenate Biomed, we believe that strong collaboration goes beyond the workplace. We spent a wonderful time together, filled with creativity and connection that strengthen the bonds that drive our mission forward. Moments like these remind us that innovation starts with people. #Teamwork #RejuvenateBiomed #HealthyAging #StrongerTogether
- Rejuvenate Biomed is ready for #BIO2026! We are excited to actively participate in the world’s largest biotechnology convention, bringing together leaders from biotech, pharma, and the investment community. Our team will be represented by: 👉 Ann Belien, PhD, Founder & CEO 👉 Lizzy-Anne (Lisiane) Neven, CFO 👉 David Brooks, PhD, Business Development Lead We’re especially proud that Ann will be speaking in two inspiring sessions: 📅 22 June 2026 | 4:15 – 5:15 PM Reclaiming the Impossible: Biotech Leaders on Breaking Through in
Something wrong or missing? Send an update. Fixed within 24 hours.